vs

Side-by-side financial comparison of HARROW, INC. (HROW) and McEwen Inc. (MUX). Click either name above to swap in a different company.

HARROW, INC. is the larger business by last-quarter revenue ($89.1M vs $64.6M, roughly 1.4× McEwen Inc.). McEwen Inc. runs the higher net margin — 59.0% vs 7.4%, a 51.6% gap on every dollar of revenue. On growth, McEwen Inc. posted the faster year-over-year revenue change (92.8% vs 33.3%). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 25.2%).

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.

McEwen Inc (ticker MUX) is a natural resource company primarily engaged in the exploration, development, and production of gold, silver, and copper assets. Its core operations are located across North and South America, serving global commodity markets with a focus on sustainable, responsible mining practices.

HROW vs MUX — Head-to-Head

Bigger by revenue
HROW
HROW
1.4× larger
HROW
$89.1M
$64.6M
MUX
Growing faster (revenue YoY)
MUX
MUX
+59.5% gap
MUX
92.8%
33.3%
HROW
Higher net margin
MUX
MUX
51.6% more per $
MUX
59.0%
7.4%
HROW
Faster 2-yr revenue CAGR
HROW
HROW
Annualised
HROW
60.5%
25.2%
MUX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HROW
HROW
MUX
MUX
Revenue
$89.1M
$64.6M
Net Profit
$6.6M
$38.1M
Gross Margin
79.3%
26.9%
Operating Margin
17.5%
34.2%
Net Margin
7.4%
59.0%
Revenue YoY
33.3%
92.8%
Net Profit YoY
-2.2%
563.1%
EPS (diluted)
$0.20
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HROW
HROW
MUX
MUX
Q4 25
$89.1M
$64.6M
Q3 25
$71.6M
$50.5M
Q2 25
$63.7M
$46.7M
Q1 25
$47.8M
$35.7M
Q4 24
$66.8M
$33.5M
Q3 24
$49.3M
$52.3M
Q2 24
$48.9M
$47.5M
Q1 24
$34.6M
$41.2M
Net Profit
HROW
HROW
MUX
MUX
Q4 25
$6.6M
$38.1M
Q3 25
$1.0M
$-462.0K
Q2 25
$5.0M
$3.0M
Q1 25
$-17.8M
$-6.3M
Q4 24
$6.8M
$-8.2M
Q3 24
$-4.2M
$-2.1M
Q2 24
$-6.5M
$-13.0M
Q1 24
$-13.6M
$-20.4M
Gross Margin
HROW
HROW
MUX
MUX
Q4 25
79.3%
26.9%
Q3 25
75.3%
15.5%
Q2 25
74.5%
26.3%
Q1 25
67.5%
28.2%
Q4 24
78.8%
1.1%
Q3 24
75.6%
26.4%
Q2 24
74.4%
22.7%
Q1 24
69.5%
14.6%
Operating Margin
HROW
HROW
MUX
MUX
Q4 25
17.5%
34.2%
Q3 25
20.6%
-16.7%
Q2 25
17.9%
-7.2%
Q1 25
-23.5%
-21.4%
Q4 24
19.3%
-43.4%
Q3 24
2.7%
-0.2%
Q2 24
3.1%
-29.4%
Q1 24
-20.0%
-53.3%
Net Margin
HROW
HROW
MUX
MUX
Q4 25
7.4%
59.0%
Q3 25
1.4%
-0.9%
Q2 25
7.8%
6.5%
Q1 25
-37.2%
-17.6%
Q4 24
10.1%
-24.6%
Q3 24
-8.6%
-4.0%
Q2 24
-13.2%
-27.4%
Q1 24
-39.2%
-49.4%
EPS (diluted)
HROW
HROW
MUX
MUX
Q4 25
$0.20
$0.66
Q3 25
$0.03
$-0.01
Q2 25
$0.13
$0.06
Q1 25
$-0.50
$-0.12
Q4 24
$0.19
$-0.15
Q3 24
$-0.12
$-0.04
Q2 24
$-0.18
$-0.26
Q1 24
$-0.38
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HROW
HROW
MUX
MUX
Cash + ST InvestmentsLiquidity on hand
$72.9M
$72.1M
Total DebtLower is stronger
$250.0M
$126.2M
Stockholders' EquityBook value
$52.4M
$546.2M
Total Assets
$399.5M
$820.2M
Debt / EquityLower = less leverage
4.77×
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HROW
HROW
MUX
MUX
Q4 25
$72.9M
$72.1M
Q3 25
$74.3M
$75.4M
Q2 25
$53.0M
$69.5M
Q1 25
$66.7M
$79.3M
Q4 24
$47.2M
$15.3M
Q3 24
$72.6M
$30.2M
Q2 24
$71.0M
$42.6M
Q1 24
$76.0M
$22.0M
Total Debt
HROW
HROW
MUX
MUX
Q4 25
$250.0M
$126.2M
Q3 25
$347.2M
$126.0M
Q2 25
$250.6M
$125.8M
Q1 25
$256.9M
$125.5M
Q4 24
$262.7M
$40.0M
Q3 24
$230.7M
$31.0M
Q2 24
$236.3M
$34.0M
Q1 24
$243.4M
$37.0M
Stockholders' Equity
HROW
HROW
MUX
MUX
Q4 25
$52.4M
$546.2M
Q3 25
$47.0M
$488.6M
Q2 25
$49.7M
$484.5M
Q1 25
$56.5M
$479.8M
Q4 24
$69.7M
$495.0M
Q3 24
$58.0M
$502.1M
Q2 24
$58.5M
$485.2M
Q1 24
$60.6M
$482.5M
Total Assets
HROW
HROW
MUX
MUX
Q4 25
$399.5M
$820.2M
Q3 25
$363.1M
$747.6M
Q2 25
$345.0M
$735.6M
Q1 25
$364.2M
$730.6M
Q4 24
$389.0M
$664.6M
Q3 24
$351.5M
$667.8M
Q2 24
$306.6M
$645.1M
Q1 24
$295.5M
$638.7M
Debt / Equity
HROW
HROW
MUX
MUX
Q4 25
4.77×
0.23×
Q3 25
7.39×
0.26×
Q2 25
5.05×
0.26×
Q1 25
4.55×
0.26×
Q4 24
3.77×
0.08×
Q3 24
3.98×
0.06×
Q2 24
4.04×
0.07×
Q1 24
4.02×
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HROW
HROW
MUX
MUX
Operating Cash FlowLast quarter
$8.4M
$3.1M
Free Cash FlowOCF − Capex
$8.1M
FCF MarginFCF / Revenue
9.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.27×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$43.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HROW
HROW
MUX
MUX
Q4 25
$8.4M
$3.1M
Q3 25
$16.6M
$5.2M
Q2 25
$-803.0K
$478.0K
Q1 25
$19.7M
$-1.9M
Q4 24
$-17.8M
$-1.2M
Q3 24
$3.0M
$23.2M
Q2 24
$-2.7M
$3.6M
Q1 24
$-4.6M
$3.9M
Free Cash Flow
HROW
HROW
MUX
MUX
Q4 25
$8.1M
Q3 25
$16.4M
Q2 25
$-969.0K
Q1 25
$19.5M
Q4 24
$-18.3M
Q3 24
$2.3M
Q2 24
$-3.1M
Q1 24
$-4.7M
FCF Margin
HROW
HROW
MUX
MUX
Q4 25
9.1%
Q3 25
22.9%
Q2 25
-1.5%
Q1 25
40.8%
Q4 24
-27.4%
Q3 24
4.8%
Q2 24
-6.3%
Q1 24
-13.6%
Capex Intensity
HROW
HROW
MUX
MUX
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.4%
Q4 24
0.8%
Q3 24
1.2%
Q2 24
0.7%
Q1 24
0.3%
Cash Conversion
HROW
HROW
MUX
MUX
Q4 25
1.27×
0.08×
Q3 25
16.26×
Q2 25
-0.16×
0.16×
Q1 25
Q4 24
-2.62×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons